ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "FK506"

  • 2019 American Transplant Congress

    mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis

    V. N. Nguyen1, R. Abagyan2, S. Tsunoda2

    1Pharmacy, UC San Diego Health, San Diego, CA, 2Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA

    *Purpose: Our study aimed to compare the adverse events (AEs) of tacrolimus to mammalian target of rapamycin (mTOR) inhibitors in solid organ transplant patients.*Methods: Our…
  • 2019 American Transplant Congress

    Increasing Time-in-Therapeutic Range of Tacrolimus is Associated with Superior Outcomes in Living Kidney Transplants

    T. Lin, T. Song, S. Yin, Y. Jiang, Z. Huang, X. Wang, J. Liu, Z. Wang

    Organ Transplantation Center, Urology Department, Urology Research Institute, WestChina Hospital, Sichuan University, Chengdu, China

    *Purpose: Tacrolimus-based regimens remain the backbone of maintenance immunosuppressive therapy in kidney transplant, and therapeutic drug monitoring of tacrolimus is necessary due to a narrow…
  • 2019 American Transplant Congress

    CURATE.AI: Personalized Liver Transplant Tacrolimus Dosing

    A. Zarrinpar1, T. Kee2, P. Wang3, J. Khong3, U. Kim1, J. Chong2, J. B. Jeong3, A. T. Truong2, S. Tan2, B. K. Betzler2, W. Ng2, C. Ho3, D. Ho2

    1Surgery, University of Florida, Gainesville, FL, 2National University of Singapore, Singapore, Singapore, 3UCLA, Los Angeles, CA

    *Purpose: Transplant immunosuppressive regimens include multiple drugs with varying pharmacokinetics, metabolic pathways, and drug-drug interactions. This study aimed to use CURATE.AI, an artificial intelligence platform,…
  • 2019 American Transplant Congress

    LCP-Tacrolimus (LCPT; Envarsus XR) Dosing Considerations in De Novo Kidney Transplant Recipients

    D. Cibrik1, P. West-Thielke2, S. J. Patel3, D. R. Stevens4, U. Meier-Kriesche4

    1University of Kansas Medical Center, Kansas City, KS, 2University of Illinois Hospital and Health Sciences System, Chicago, Chicago, IL, 3Veloxis Pharmaceuticals, Cary, NC, 4Veloxis Pharmaceuticals Inc., Cary, NC

    *Purpose: Different initial dosing strategies were studied in Phase II/Phase III trials evaluating the pharmacokinetics, safety, and efficacy of LCPT in de novo kidney transplantation.…
  • 2019 American Transplant Congress

    Impact of Once-Daily Tacrolimus on Trough Concentration Variability in Stable Adolescent and Young Adult Renal Transplant Recipients

    M. Moss, J. Goebel, A. Lofton, E. Steinberg, M. Bock

    Children's Hospital Colorado, Aurora, CO

    *Purpose: High tacrolimus concentration variability (Vtac), likely influenced by medication non-adherence, is a risk factor for graft dysfunction and loss among renal transplant recipients (RTRs),…
  • 2019 American Transplant Congress

    Functional Characterization of Orthotopic Hind-Limb Transplants in Rats

    F. Zheng, X. Zhang, L. Qiu, J. Wang, X. Yeap, K. M. Koss, J. Wertheim, Z. J. Zhang

    Comprehensive Transplant Center and Department of Surgery, Northwestern University, Chicago, IL

    *Purpose: Vascularized composite allotransplantation (VCA) is a valid therapeutic option for patients with non-salvageable injuries such as severe burns or limb amputation. The immune response…
  • 2019 American Transplant Congress

    CYP3A5 Genotype Had No Influence on Renal Function after Renal Transplantation

    J. E. Kimpton, A. J. Hughes, I. MacPhee

    Renal Medicine and Transplantation, St George’s University Hospitals NHS Foundation Trust, London, United Kingdom

    *Purpose: Tacrolimus metabolism rate has been reported to be associated with renal function after renal transplantation (Thölking et al., 2014); this study aimed to determine…
  • 2019 American Transplant Congress

    Dosing and Exposure over 2 Years with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac) in De Novo Kidney Transplantation

    K. Budde1, S. Bunnapradist2, S. Patel3, D. Stevens3, U. Meier-Kriesche3, B. Suwelack4

    1Charité University Medicine Berlin, Berlin, Germany, 2UCLA Medical Center, Los Angeles, CA, 3Veloxis Pharmaceuticals Inc, Cary, NC, 4University Hospital of Münster, Münster, Germany

    *Purpose: A prospective study demonstrated safe and efficacious use of LCPT in de novo kidney transplantation. This study aims to evaluate tacrolimus trough levels and…
  • 2018 American Transplant Congress

    Clinical Significance of Tacrolimus Trough Level at the Early Period after Kidney Transplantation

    W. Park,1,2 S. Yeo,1 S. Kang,1,2 H. Park,1 K. Jin,1,2 S. Park,1,2 S. Han.1,2

    1Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea; 2Keimyung University Kidney Institute, Daegu, Republic of Korea.

    Background:The stable immunosuppressant level at the early period after kidney transplantation (KT) is one of the most important factors to decide the prognosis of KT.…
  • 2018 American Transplant Congress

    Tacrolimus and Isavuconazole Therapy: What about the Drug Interaction?

    C. Gill,1 N. Mercuro,1 R. Kenney,1 A. Jantz,1 B. Summers,1 N. Sulejmani,1 S. Davis.1,2

    1Henry Ford Hospital, Detroit; 2Wayne State University, Detroit, MI.

    Introduction:Isavuconazole (ISV) is a triazole antifungal that is often utilized in solid organ transplant recipients (SOTR) for the treatment of invasive aspergillosis and mucormycosis. Isavuconazole…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences